ANRO:NYE-Alto Neuroscience, Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.39

Change

-0.26 (-7.12)%

Market Cap

USD 0.12B

Volume

0.33M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

-0.18 (-0.47%)

USD 3.93B
RCUS Arcus Biosciences Inc

-0.10 (-0.80%)

USD 1.19B
NUVB Nuvation Bio Inc

-0.10 (-4.20%)

USD 0.78B
DNA Ginkgo Bioworks Holdings

-0.73 (-5.12%)

USD 0.62B
CYBN Cybin Inc

+0.37 (+4.11%)

USD 0.20B
PLX Protalix Biotherapeutics Inc

-0.11 (-4.14%)

USD 0.20B
ADCT ADC Therapeutics SA

-0.04 (-2.65%)

USD 0.16B
ARMP Armata Pharmaceuticals Inc

-0.06 (-2.88%)

USD 0.07B
OSTX OS Therapies Incorporated

-0.06 (-3.06%)

USD 0.07B
ANVS Annovis Bio Inc

-0.20 (-6.80%)

USD 0.06B

ETFs Containing ANRO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.86% 29% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.86% 29% F 2% F
Trailing 12 Months  
Capital Gain -75.66% 41% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.66% 41% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.07% 37% F 26% F
Dividend Return -1.07% 37% F 16% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.11% 94% A 81% B-
Risk Adjusted Return -11.69% 26% F 14% F
Market Capitalization 0.12B 77% C+ 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector